Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O95340

UPID:
PAPS2_HUMAN

ALTERNATIVE NAMES:
Sulfurylase kinase 2

ALTERNATIVE UPACC:
O95340; Q9BZL2; Q9P0G6; Q9UHM1; Q9UKD3; Q9UP30

BACKGROUND:
Sulfurylase kinase 2, with its alternative name Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 2, is pivotal in the sulfate activation pathway, facilitating the synthesis of PAPS from ATP. This process is vital for sulfation activities in mammals, underscoring the enzyme's importance in metabolic pathways and its contribution to sulfate homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in skeletogenesis, mutations affecting Sulfurylase kinase 2 are linked to Brachyolmia type 4, manifesting in short stature and skeletal abnormalities. Exploring the functions and mechanisms of this enzyme could lead to innovative therapeutic approaches for skeletal dysplasias, offering hope for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.